This report provides an overview of global COVID-19 clinical trials extracted from the publisher's Pharma Intelligence Center on March 30, 2022. The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines versus therapeutics, trials impacted by COVID-19, and testing/vaccination data.
Scope
- The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database. The data included clinical trials, which were captured in the database as of March 30, 2022. The trials were analyzed and segmented by all COVID-19 trials, trials using vaccines, trials using therapeutics, and all trials impacted due to the pandemic. An analysis was also completed on COVID-19 testing and vaccination data.
Reasons to Buy
- Trends of COVID-19 trials by phase, sponsor type and status
- Geographical distribution of COVID-19 trials
- Comparison of COVID-19 trials by vaccines versus therapeutics
- Impact of COVID-19 of clinical trials
- COVID-19 testing and vaccination data
Table of Contents
- Executive Summary
- Introduction
- Analysis of COVID-19 Clinical Trials
- COVID-19 Clinical Trials for Vaccines
- COVID-19 Clinical Trials for Therapeutics
- COVID-19 Testing and Vaccination Data
- Impact of COVID-19 on Clinical Trials
- Key Findings
- Appendix
List of Tables
Table 1: Top Countries in COVID-19 Key Stats
List of Figures
Figure 1: Impact of COVID-19
Figure 2: Top Countries in COVID-19 Key Stats
Figures 3 & 4: Over 2,000 Vaccines and Therapeutics Are in Development
Figure 5: Number of COVID-19 Clinical Trials by Start Date, by Month
Figure 6: Number of COVID-19 Clinical Trials, by Multinational vs. Single Country
Figure 7: Single Country COVID-19 Clinical Trials, by Region & Phase
Figure 8: Multinational Country COVID-19 Clinical Trials, by Region & Phase
Figure 9: COVID-19 Clinical Trial Sites, by Region
Figures 10 & 11: COVID-19 Clinical Trial Sites, by Country & State
Figures 12 & 13: Number of COVID-19 Clinical Trials, by Phase & Status
Figure 14: Endpoint Status for Completed COVID-19 Clinical Trials
Figure 15: Top Reasons for Terminated Trials, by Phase
Figure 16: Top Reason for Terminated Trials, by Sponsor Type
Figure 17: Long COVID-19 Clinical Trials, by Trial Start Date
Figures 18 & 19: Average Completed Trial Duration for Viral Infections in General vs. COVID-19, by Phase
Figure 20: COVID-19 Clinical Trials by Vaccine, by Trial Start Date
Figures 21 & 22: Vaccine COVID-19 Clinical Trials, by Phase & Status
Figure 23: Vaccine COVID-19 Clinical Trials, by Sponsor Type
Figure 24: Top Industry Sponsors for COVID-19 Vaccine Clinical Trials
Figure 25: Top Non-Industry Sponsors for COVID-19 Vaccine Clinical Trials
Figure 26: Upcoming Filings and Regulatory Approvals for COVID-19 Vaccines
Figure 27: COVID-19 Therapeutic Clinical Trials, by Trial Start Date
Figures 28 & 29: Therapeutic COVID-19 Clinical Trials, by Phase & Status
Figure 30: Therapeutic COVID-19 Clinical Trials, by Sponsor Type
Figure 31: Top Industry Sponsors for COVID-19 Therapeutic Clinical Trials
Figure 32: Top Non-Industry Sponsors for COVID-19 Therapeutic Clinical Trials
Figure 33: Upcoming 2022 Filings and Regulatory Approvals for Therapeutic COVID-19 Drugs
Figure 34: Cumulative Number of COVID-19 Tests, by Country
Figure 35: COVID-19 Tests Per Thousand People, by Country
Figures 36 & 37: Cumulative Number of Fully Vaccinated People per 1M & Number of Vaccinations by Month per 1M, by Country
Figure 38: Fully Vaccinated Population Rate, by Country
Figures 39 & 40: Percent of Population Received One Dose & Percent of Population Received Second Dose, by Country
Figure 41: US COVID-19 Vaccination Administration by Vaccine Type vs. Number of People Fully Vaccinated per 1M
Figure 42: Percent of People in the US Who Received Booster Shoes, by Primary Booster Type
Figure 43: Clinical Trials Disrupted Due to COVID-19
Figures 44 & 45: Disrupted Clinical Trials, by Reason
Figure 46: Disrupted Clinical Trials, by Therapy Area
Figure 47: Disrupted Clinical Trials Relative to Ongoing and Planned Trials, by Therapy Area
Figures 48 & 49: Disrupted Clinical Trials Activities, by Region & Country
Figure 50: Disrupted Clinical Trials, by Top Sponsors
Figure 51: Resumed Clinical Trials After Being Disrupted Due to COVID-19
Figure 52: Percent of Decentralized Clinical Trials, By Start Year
Figure 53: Virtual Components Used In Decentralized Clinical Trials
